The estimated Net Worth of Abraham N. Oler is at least 24.5 千$ dollars as of 28 January 2022. Mr. Oler owns over 1,500 units of Onconova Therapeutics Inc stock worth over 24,514$ and over the last 5 years he sold ONTX stock worth over 0$. In addition, he makes 0$ as Vice President、 Corporate Development and General Counsel at Onconova Therapeutics Inc.
Abraham has made over 11 trades of the Onconova Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,500 units of ONTX stock worth 2,505$ on 28 January 2022.
The largest trade he's ever made was buying 75,000 units of Onconova Therapeutics Inc stock on 25 November 2019 worth over 15,000$. On average, Abraham trades about 9,493 units every 47 days since 2019. As of 28 January 2022 he still owns at least 24,514 units of Onconova Therapeutics Inc stock.
You can see the complete history of Mr. Oler stock trades at the bottom of the page.
Abraham N. Oler is Vice President, Corporate Development and General Counsel of the company. Mr. Oler served most recently as Vice President of Operations and Chief of Staff to the CEO of Spectrum Pharmaceuticals. During his tenure, he was instrumental in the company's progress and productive licensing activities. He served in varied roles of increasing responsibility, as a member of the executive management team, the corporate development team, and as Head of Alliances and Legal Affairs. Due to a series of successful accomplishments, he was named Chief of Staff.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over 1,631,795$ worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth 51,994,589$ . The most active insiders traders include Capital, Llc Armistice Capi...、Capital Management, Llc 683、Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of 294,478$. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth 8,666$.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: